SYDNEY (Reuters) - Australian biotech group Innate Immunotherapeutics Limited (IIL.AX) said on Thursday it was not under investigation in an insider trading case involving Republican U.S. congressman Christopher Collins.
In a statement, the company said it had cooperated fully with requests for information from the U.S. Securities and Exchange Commission (SEC).
“The Company and its directors/officers (excepting Mr. Collins) are not under investigation. The Company considers the ongoing investigation to be a private matter to Mr. Collins,” the statement said.
Collins retired as a director of Innate in early May and was no longer involved with the governance of the company, the statement said.
Reporting by Wayne Cole; Editing by Muralikumar Anantharaman